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Abstract
Aggregation of misfolded proteins is characteristic of a number of neurodegenerative diseases, including
Huntington disease (HD). The CCT/TRiC (chaperonin containing TCP-1/TCP-1 ring) chaperonin complex can
inhibit aggregation and cellular toxicity induced by expanded repeat Huntingtin (mHtt) fragments. The
substrate-binding apical domain of CCT/TRiC subunit CCT1, ApiCCT1, is sufficient to inhibit aggregation of
expanded repeat mHtt fragments in vitro, providing therapeutic promise for HD. However, a key hurdle in
considering ApiCCT1 as a potential treatment is in delivery. Because ApiCCT1 has a region of similarity to the HIV
Tat protein cell-transduction domain, we tested whether recombinant ApiCCT1 (ApiCCT1r) protein could enter
cells following exogenous delivery and modulate an established panel of mHtt-mediated cell-based phenotypes.
Cell fractionation studies demonstrate that exogenous ApiCCT1r can penetrate cell membranes and can localize
to the nucleus, consistent with a strategy that can target both cytosolic and nuclear pathogenic events in HD.
ApiCCT1r application does indeed modulate HD cellular phenotypes by decreasing formation of visible inclusions,
fibrillar oligomers, and insoluble mHtt derived from expression of a truncated mHtt exon 1 fragment.
ApiCCT1r also delays the onset of inclusion body formation as visualized via live imaging. ApiCCT1r reduces mHttmediated toxicity in immortalized striatal cells derived from full-length knock-in HD mice, suggesting that
therapeutic benefit may extend beyond effects on aggregation. These studies provide the basis for a potentially
robust and unique therapeutic strategy to target mHtt-mediated protein pathogenesis.

Huntington disease (HD) is a devastating neurodegenerative disorder that strikes in midlife and is characterized
by movement abnormalities, psychiatric symptoms, and cognitive deficits, as well as by the accumulation of
pathogenic proteins and peptides (1–3). Currently no disease-modifying therapy is available. The disease is
caused by an abnormal CAG repeat expansion in the HD gene, leading to the production of an expanded
polyglutamine repeat in the amino terminal domain of the Huntingtin protein (Htt) (2, 3). A hallmark of HD is the
propensity for the mutant protein (mHtt) to misfold and aggregate (1). While the connection between large
fibrillar deposits and neurodegeneration is not clear, accumulation and aggregation of mHtt is likely to result
from a deficit in cellular quality control machinery and can be used as a surrogate outcome measure for disease
progression.

Molecular chaperones, which are colocalized within mHtt inclusion bodies, suppress neurodegeneration in
several animal models of protein misfolding diseases, including HD (4–7). For instance, overexpression of Hsp70
and Hsp40 suppresses neurodegeneration in animal models of polyglutamine diseases (8, 9). In parallel, deletion
of Hsp70 markedly worsens pathogenesis in a mouse model of HD (10). Chaperones are thought to suppress the
toxicity of disease-associated proteins through direct effects on their misfolding and clearance; however, the
mechanisms are not well understood.
The 1MDa CCT/TRiC (TCP1-ring complex) chaperonin is an ATP-dependent, ring-shaped hetero-oligomeric
chaperone that binds and folds newly translated polypeptides (11). A genome-wide RNAi screen
in Caenorhabditis elegans identified six of the eight subunits of CCT (1, 2, 4–7) as suppressors of polyglutamine
aggregation (12). CCT/TRiC expression also prevents mHtt aggregation in cell and yeast models of HD (13–16).
Further, overexpression of one subunit of the TRiC/CCT complex, CCT1, is sufficient to inhibit aggregation and
reduce mHtt-mediated toxicity in mouse N2a neuronal cells (15). CCT/TRiC can also suppress aggregation in
vitro, using purified components (15). Reduction to just the 20 kDa substrate-binding apical domain of yeast
CCT1 (ApiCCT1) inhibits aggregation of recombinant mHtt in vitro, potentially through its ability to bind to the Nterminal 17 amino acid domain of Htt. This domain is involved in multiple Htt functions and in aggregation
kinetics of mHtt (15). However, the efficacy of this apical domain has not yet been tested in HD cell models.
Given the potential of ApiCCT1 as a therapeutic for the treatment of HD, we tested if recombinant yeast
ApiCCT1 (ApiCCT1r) protein could alter the aggregation and neurotoxicity of mHtt in selected proof-of-concept
assays when purified protein was directly added to the culture media of cellular models of HD. We hypothesized
that ApiCCT1r could be directly taken up by cells given the potential similarity of a positively charged region in
Api1 to the protein transduction domain of the HIV protein Tat. We establish here that exogenously delivered
ApiCCT1r can penetrate cell membranes, supporting the idea that ApiCCT1r has potential therapeutic application
without necessitating intracellular expression. Of note, ApiCCT1r can cofractionate with nuclear fractions, which
is significant in the context of nuclear accumulation and toxicity mediated by mHtt (1, 12, 17, 18). Application of
just the apical domain of recombinant yeast CCT1 to rat pheochromocytoma-derived PC12 cells stably
expressing truncated mutant Htt exon 1 protein (mHttex1p) (14A2.6 cells) decreased the formation of
oligomeric and insoluble mHtt and slowed the kinetics of inclusion body formation in 14A2.6 cells. Finally,
ApiCCT1r rescued mHtt-mediated toxicity in mouse striatal STHdhQ109/HdhQ109 cells derived from a knock-in
mouse model of HD. Together these results provide a rationale for future testing of extracellular infusion of
ApiCCT1r or cell-based delivery of secreted forms of ApiCCT1 to alleviate HD phenotypes in vivo.

Results
Purified ApiCCT1r Is Taken Up by Cells Following Exogenous Delivery.
Chaperones target protein homeostasis cellular processes and have significant potential to modulate the protein
misfolding and accumulation that appears key to many neurodegenerative diseases (19). Previous in vitro results
suggest that expression of ApiCCT1 in neurons might reduce the misfolding and accumulation of mHtt. However,
extensive molecular manipulations would be required for intracellular expression of ApiCCT1 in cells in the
brain; therefore, strategies to deliver ApiCCT1 extracellularly and be taken up by cells could be highly beneficial
(Fig. 1A). It is a well-established phenomenon that some exogenously delivered proteins, specifically cellpenetrating peptides (CPPs), can cross membranes to enter cells and even nuclei (20, 21). There are no specific
primary sequences common to all CPPs; however, many have a high abundance of positively charged amino
acids or an alternating pattern of charged and hydrophobic residues (22, 23). This includes one of the first and
most highly studied CPPs, the transactivator of transcription (TAT) protein of HIV (20, 21). To evaluate the
possibility of directly introducing ApiCCT1 into cells expressing mHtt, we compared the sequence of yeast

ApiCCT1r and TAT. Fortuitously, we find that ApiCCT1r does contain a region with a similar abundance of
positively charged amino acids (Fig. 1B), providing a rationale to test exogenous application of ApiCCT1.

Fig. 1. Exogenous ApiCCT1r enters cells and localizes to the cytosol and nucleus of PC12 cells. (A) Schematic of
possible protein transduction by yeast ApiCCT1r. (B) Comparison of yeast ApiCCT1 to HIV Tat. (C) Fractionation of
14A2.6 treated with ApiCCT1r. Induced 14A2.6 cells treated with ApiCCT1r were treated with PK before lysis,
then lysed (T) and fractionated into cytoplasmic (C) and nuclear (N) fractions, and analyzed by SDS/PAGE with
Western blotting. Nuclei were also treated with PK before lysis. Media from the cells was also analyzed for the
presence of ApiCCT1r. Lanes are labeled as follows: –PK, no PK treatment; Api1, no ApiCCT1r as a control;
PK+ctrl, a positive control for PK treatment. In the latter case, the nuclear extract was treated with PK for 30 min
on ice. The final lane is ApiCCT1r loaded as a standard. The blot was probed with anti-His antibody (ApiCCT1r),
anti-GAPDH (cytoplasmic marker), anti-p84 (nuclear marker), and anti-EGFP (Htt). We loaded 30µg of total
protein in each lane except for the media which only had 10 µg of protein loaded to avoid overexposure.
To test the hypothesis that ApiCCT1 can enter cells, a biochemical approach was used to determine whether
ApiCCT1 cofractionated with cytosolic or nuclear cellular fractions. ApiCCT1r was added to the media of PC12
cells, Htt14A2.6, that inducibly express a truncated form of expanded repeat Htt exon 1 protein fused at the C
terminus to enhanced green fluorescent protein (EGFP) (24), and cell fractionations performed. 14A2.6 cells
induced with Ponasterone A were simultaneously treated with a single application of 1 µM ApiCCT1r for 48 h.
Before lysis, cells were treated with 90 μg/mL proteinase K (PK) to digest any extracellular protein associated
with the cell surface. Following lysis, the total extract (T) was fractionated into cytoplasmic (C) and nuclear (N)
fractions. Intact nuclei were again treated with PK before lysis to remove any proteins bound to the exterior of
the nuclear membrane. All fractions were analyzed by SDS/PAGE followed by Western analysis (Fig. 1C). Blots
were probed with anti-His antibody (ApiCCT1r), anti-GAPDH (cytoplasmic marker), anti-p84 (nuclear marker),
and anti-EGFP (mHtt). As expected, the majority of the ApiCCT1r remains in the media and a significant fraction
appears trapped in the cell membrane as ApiCCT1r levels are lower upon PK treatment. This finding precluded
analysis of cellular localization by immunofluorescence using available antibodies. However, ApiCCT1r is clearly

visible in the PK-treated samples, indicating that the ApiCCT1r does enter cells (red box). Moreover,
ApiCCT1r appears to localize both within the cytosolic and nuclear fractions, suggesting the availability of
ApiCCT1 to act in both compartments. Although levels of ApiCCT1r appear to be higher in nuclear versus
cytoplasmic fractions, this may be due to the fact that ApiCCT1 makes up a smaller percentage of the total
protein in the cytoplasm. To ensure that the ApiCCT1r was not bound to aggregated mHtt or trapped within
aggregates, the experiment was repeated using uninduced cells, where mHtt aggregates are absent. ApiCCT1r is
still found within the cytoplasm and nuclei of these cells (Fig. S1), indicating that the entry of ApiCCT1r into cells
is independent of the presence of mHtt aggregates.

Exogenous Delivery of ApiCCT1r Reduces Multiple Aggregation Species in PC12 Cells
Stably Expressing Truncated Httex1p.

To evaluate the therapeutic potential of exogenous delivery of ApiCCT1r, a panel of established cell-based assays
was used to monitor effects on specific aggregation species and cellular toxicity. We first tested whether
ApiCCT1r could modulate visible inclusion formation, which is a highly utilized first assessment of altered
aggregation. Exogenous delivery to 14A2.6 cells significantly decreased the number of visible inclusions
following induction and ApiCCT1r application (one-way ANOVA: F = 3.933, P = 0.0037; Dunnett’s multiple
comparison test: 0 µM vs. 0.5 µM, P < 0.05; 0 µM vs. 1 µM, P < 0.01; and 0 µM vs. 2.5 µM, P < 0.05) (Fig.
2 A and B). To determine whether this reduction is accompanied by a concomitant increase in monomeric,
soluble Htt, Htt monomer levels from the same experiments were examined by Western analysis. ApiCCT1r does
not appear to alter monomer levels (one-way ANOVA: F = 0.1908, P = 0.9604) or expression levels (Fig.
2 C and D and qPCR), suggesting that ApiCCT1r does not interfere with Htt expression and does not alter the
steady-state levels of monomeric mHtt and no obvious differences in cell numbers following ApiCCT1r delivery
were observed.

Fig. 2. ApiCCT1r reduces the number of cells containing visible inclusions but does not increase levels of
monomeric mHtt in 14A2.6 cells. (A and B) The 14A2.6 cells were treated with ApiCCT1r at the concentrations
listed for 48 h. Cells were then fixed, imaged at 20× magnification, and the number of cells containing inclusion
bodies was counted by fluorescence microscopy. (A) Representative images used for quantitation. Scale bar, 20
μm. (B) ApiCCT1r significantly decreases the number of visible inclusions in the 14A2.6 cells (Dunnett’s multiple
comparison test, *P < 0.05, **P < 0.01). Error bars represent group means ± SEM. (C and D) The 14A2.6 cells
were treated with ApiCCT1r at the concentrations listed for 48 h. SDS/PAGE analysis of lysates shows no
significant differences in monomeric mHtt levels with ApiCCT1r treatment. Blots were probed with anti-EGFP
(mHtt) and anti-actin (loading control). Error bars represent group means ± SEM.

Insoluble Htt aggregates and mHtt oligomers are hallmarks of HD (1, 17, 25). In particular, oligomeric mHtt
species are thought to be a major source of toxicity in affected neurons (25). Accordingly, mHtt oligomers and
insoluble Htt species were next evaluated to determine whether exogenous delivery of ApiCCT1r influences
accumulation of these forms. We used SDS agarose gel electrophoresis (AGE) to resolve oligomeric species, as
this approach seems to preferentially resolve fibrillar oligomers of mHtt (26–29). Equivalent amounts of protein
from cell lysates were loaded on SDS–AGE gels. We observed that ApiCCT1 application caused a dose-dependent
decrease in both the level of mHtt oligomers (one-way ANOVA: F = 4.548, P = 0.0047; Dunnett’s multiple
comparison test: 0 µM vs. 0.5 µM, P < 0.05; 0 µM vs. 1 µM, P < 0.01; 0 µM vs. 2.5 µM, P < 0.01) (Fig. 3 A and B)
and the amount of SDS-insoluble mHtt (one-way ANOVA: F = 17.91, P < 0.0001; Dunnett’s multiple comparison
test: 0 µM vs. 1 µM, P < 0.01; 0 µM vs. 10 µM, P < 0.001) (Fig. 3 C and D). These data indicate that exogenous
ApiCCT1r application is able to reduce the formation of oligomeric and insoluble mHtt as well as large visible
inclusions, suggesting that ApiCCT1r may have effects on both protein misfolding and/or protein accumulation
and that exogenous application is sufficient to modulate these readouts.

Fig. 3. ApiCCT1r decreases fibrillar oligomers and insoluble mHtt and delays inclusion body formation in 14A2.6
cells. (A–F) The 14A2.6 cells were treated with ApiCCT1r at the concentrations listed for 48 h. Cells were lysed
and analyzed for different conformations of mHtt. (A and B) Lysates were analyzed by SDS-AGE with Western
blotting and membranes were probed with anti-EGFP (mHtt). There is a dose-dependent decrease in the level of
mHtt oligomers (Dunnett’s multiple comparison test, *P < 0.05, **P < 0.01). Error bars represent group means ±
SEM. (C and D) ApiCCT1r significantly decreases the amount of SDS-insoluble mHtt (Dunnett’s multiple
comparison test, **P < 0.01, ***P < 0.001) by filter-retardation assay. Membranes were probed with anti-EGFP
antibody (mHtt). Error bars represent group means ± SEM. (E) ApiCCT1r delays the formation of visible inclusions
in the 14A2.6 cells (Dunnett’s multiple comparison test, ***P < 0.001) by live cell imaging visualizing EGFPtagged mHtt inclusion bodies. Error bars represent group means ± SEM.

ApiCCT1r Delays Inclusion Body Formation in 14A2.6 Cells.

To investigate whether kinetics of aggregation could be affected, a live-cell imaging assay system was used to
determine whether altered kinetics is observed, specifically targeting the lag phase in inclusion formation (28).

Strikingly, ApiCCT1r delays the formation of visible inclusions in the 14A2.6 cells (one-way ANOVA: F = 5.769, P =
0.0011; Dunnett’s multiple comparison test: 0 µM vs. 2.5 µM, P < 0.001) from 15.2 h to 18.3 h (Fig. 3E and Movie
S1), suggesting that ApiCCT1r might be delaying the formation of the “seed” that initiates the formation of
visible inclusions. These data further support altered protein homeostasis as causative of inclusion formation
and suggest that, from a therapeutic standpoint, delivery of ApiCCT1 could delay the onset of HD phenotypes.

Exogenous ApiCCT1r Reduces mHtt-Mediated Toxicity in a Knock-in Cell Model of HD.

Overexpression of the CCT1 subunit can reduce mHtt-mediated toxicity in mouse neuronal N2a cells (15). We
next determined if the apical domain of CCT1 alone could also ameliorate mHtt-mediated toxicity in cells and
whether exogenous application of this would be sufficient. To test neurotoxicity, striatal STHdhQ109/HdhQ109 cells
were used. These are striatal progenitor cells immortalized by a temperature-sensitive large T antigen, derived
from a knock-in mouse model of expanded polyglutamines (30) and expressing full-length mHtt within the
endogenous mouse locus. Upon temperature shift and serum withdrawal, mHtt lines show decreased viability
and increased cell death compared with the same cells at time 0 immediately before this shift (31). This control
is used instead of comparing to a line expressing wild-type HTT due to clonal variability between lines. Cell
viability was measured using an XTT (sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium inner salt) colorimetric cell proliferation assay to detect altered cellular metabolic
activities. Results are presented as percent relative to cells not treated with ApiCCT1r following shift to
nonpermissive conditions. Exogenous delivery of ApiCCT1r reduced mHtt-mediated toxicity in
STHdhQ109/HdhQ109 cells, depicted graphically as an increase in cellular respiration (XTT), at both 24 and 48 h after
temperature shift and addition of ApiCCT1r (24 h one-way ANOVA: F = 8.154, P = 0.0013; 48 h one-way
ANOVA: F = 78.91, P < 0.0001) (Fig. 4). This corresponds to a percent rescue of 38.4% (0.5 μM) and 46.5% (1 μM)
at 24 h and 75.5% (0.5 μM) and 79.7% (1 μM) at 48 h. Post hoc analysis with Dunnett’s multiple comparison test
revealed significant differences between the control (0 µM) and treatment (0.5 and 1 µM) groups at 24 h (P <
0.01 and P < 0.01, respectively) and 48 h (P < 0.001 and P < 0.001, respectively). This effect is not due simply to
changes in proliferation, as these cells have significantly reduced cell division following inactivation of the large T
antigen following shift to nonpermissive conditions. Interestingly, this effect persists after 48 h, suggesting that
the exogenous ApiCCT1r may have a sustained effect on cell survival.

Fig. 4. ApiCCT1r reduces mHtt-mediated toxicity in a knock-in cell model of HD. ApiCCT1r increases survival of
STHdhQ109/HdhQ109 cells at both 24 and 48 h after treatment and temperature shift (Dunnett’s multiple
comparison test, *P < 0.05, ***P < 0.001) by XTT assay. Samples were normalized to the vehicle control. Values
over 100% indicate higher o.d. and therefore increased respiration likely due to increased cell survival. Error bars
represent group means ± SEM.

Discussion
Protein homeostasis mechanisms and protein accumulation is impacted in HD and other neurodegenerative
diseases and targeted modulation of the chaperone network has been considered an attractive therapeutic
target (19). Previous studies demonstrated that overexpression of CCT1 can alter HD phenotypes in cell models
of HD and that the apical subunit of yeast CCT1 (ApiCCT1r) alone interacts with recombinant mHtt in vitro and
inhibits aggregation (15, 16). Therefore, if exogenous delivery of ApiCCT1r to cells could modulate intracellular
aggregation and toxicity, the need for overexpression of the protein inside the cell would be circumvented and
provide a rational option for delivery to the brain. We investigated this possibility in a series of targeted proofof-concept assays and find that exogenous delivery of ApiCCT1r can enter cells and modulate cellular
phenotypes.
There is established precedence for exogenous proteins crossing cell membranes and entering cells by several
different mechanisms direct penetration, pore formation, endocytosis, and transporter-mediated cell entry
(20, 21). Experiments are ongoing to determine the mechanism of ApiCCT1r cell entry with the goal of optimizing
the amount of protein that can enter cells in culture and ultimately in brain. These experiments will include
mutating the positive charged amino acid domain of yeast ApiCCT1 to determine if this domain is required.
Additionally, testing whether exogenous application of human ApiCCT1r also results in cell entry and phenotypic
modulation is in progress. As ApiCCT1r does not contain a known nuclear localization signal (32), perhaps the
ability to penetrate membranes similar to CPPs might explain the ability of ApiCCT1r to cofractionate with
nuclear proteins. Alternatively, the small size of this chaperone domain would allow it to passively diffuse
through the nuclear pore (33). The finding that exogenous ApiCCT1r delivery can be taken up by cells and
localizes to both the cytosol and nucleus are highly significant given that both compartments appear to
contribute to pathogenic effects mediated by chronic mHTT expression (34), in particular nuclear accumulation
of mHtt exerts toxic effects (1, 12, 17, 18).
ApiCCT1r may be directly interacting with mHtt to alter aggregation and toxicity, consistent with the previous
finding that ApiCCT1r can by itself suppress formation of insoluble mHtt aggregates and interacts with the first
17 amino acids of Htt, which regulates aggregation kinetics and other Htt functions (16). Given that toxicity is
ameliorated in a cell model expressing full-length mHtt in which inclusions are not observed, it is likely that
ApiCCT1r exerts direct effects on mHtt-mediated phenotypes beyond interference with aggregation.
Experiments to evaluate whether there is a direct association between mHTT and exogenously delivered
ApiCCT1r as anticipated and whether ApiCCT1r selectively binds to specific aggregation intermediates of mHTT
are in progress. It is also possible that ApiCCT1r also exerts extracellular effects. Further study is required to
elucidate the mechanism of action of this chaperone protein upon cellular mHTT-mediated phenotypes.
When a cell-based assay designed to screen for altered inclusion body formation was performed (24),
exogenous ApiCCT1r protein reduced the formation of visible aggregates, consistent with previous in vitro
results. Using this assay, ApiCCT1r was also found to significantly delay the formation of inclusion bodies. While
it is not yet known if this delay is protective, it is encouraging that ApiCCT1r might be able to slow the onset of
HD phenotypes.
ApiCCT1r decreased oligomeric and insoluble mHtt in an inducible cell model of HD. It is of interest to compare
these findings with previous work demonstrating that the entire TRiC/CCT complex increased the formation of
nontoxic, SDS-soluble mHtt oligomers (13). Additionally, Hsp70 and Hsp40 were required for the assembly of the
nontoxic oligomers, suggesting that for this system, increased expression of both of these chaperones might be
necessary for the formation of the nontoxic oligomeric species. Of note, the SDS-AGE technique used here
specifically resolves fibrillar SDS-resistant oligomers, raising the possibility that SDS-resistant and SDS-soluble
oligomers, respectively, represent toxic and benign oligomeric species.

The decrease in both oligomeric and insoluble mHtt is important as it is not currently known whether insoluble
or oligomeric mHtt induce toxicity in HD. Given that oligomeric mHtt levels are decreased, ApiCCT1r appears to
be intervening at the initiating events in the aggregation pathway. Further, ApiCCT1r does not alter the steadystate levels of monomeric mHtt or the expression of the transgene. Because there is no accumulation of
monomeric mHtt, which might be expected given the decreased inclusion body formation, it is possible that
clearance of the protein might be increased. Alternatively, ApiCCT1r might be remodeling mHtt conformation to
either refold misfolded mHtt or produce nontoxic species that are off-pathway to the formation of fibrillar and
amyloid species. Further studies to determine the effect of ApiCCT1r on protein folding, conformation, and
clearance, such as misfolding of sensor proteins such as dihydrofolate reductase (35), proteasomal activity, or
autophagic flux (36) assays will be necessary to understand the mechanisms by which ApiCCT1r alters
aggregation and toxicity.
While mechanisms underlying ApiCCT1r cell uptake and modulation of mHtt aggregation have yet to be
determined, the data described here provide proof-of-concept evidence that exogenous delivery of just the 20
kDa apical domain of CCT1 is sufficient to alter a panel of cellular mHTT phenotypes and could have profound
therapeutic potential without the need to create approaches for intracellular expression of the protein. Indeed,
there is support for the feasibility of direct protein delivery in vivo with administration of DJ-1 protein to the
brains of 6-Hydroxydopamine (6-OHDA) lesioned rat models of Parkinson’s disease resulting in neuroprotective
outcomes (33, 37). Further optimization to increase the efficiency of ApiCCT1r transduction into cells and nuclei
might also increase the potency of ApiCCT1r as a therapeutic reagent and is under current investigation. Given
the data presented here, the efficacy of in vivo delivery into striatum of HD mouse models can now be
investigated and optimized, including cell transplantation-based secretion of ApiCCT1, viral injections of cDNAs
encoding secreted forms of ApiCCT1, and direct protein delivery of recombinant protein.

Materials and Methods
Inducible PC12 Cells.
The Htt14A2.6 PC12 line was generated and propagated as described in ref. 24.

Protein.
The 6×-his tagged
ApiCCT1r (MVPGYALNCTVASQAMPKRIAGGNVKIACLDLNLQKARMAMGVQINIDDPEQLEQIRKREAGIVLERVKKIIDAGA
QVVLTTKGIDDLCLKEFVEAKIMGVRRCKKEDLRRIARATGATLVSSMSNLEGEETFESSYLGLCDEVVQAKFSDDECILIKGTSKAA
AAALEHHHHHH) was used as a stock of 87 µM in apical buffer [50 mM Hepes, pH 7.5, 300 mM NaCl, 10%
(vol/vol) glycerol, 1 mM DTT]. Apical buffer was used as a vehicle control. Purification was conducted as
previously described (15, 16).

Cellular Fractionation.
Cell fractionation was adapted from ref. 38, but the protocol was terminated after the lysing of the nuclei as
purification of nucleoli was not required. PK treatment was performed as described in ref. 39. Briefly, 14A2.6
cells were grown as described above. At 24 h after plating, cells were induced with Ponasterone A (PA) and
treated with 6×-His-tagged ApiCCT1r. Cells were then allowed to grow for 48 h without additional treatment
with ApiCCT1r. Cells were harvested and spun down at 1,000× g for 5 min at 4 C. A small volume of media was
retained to determine the amount of ApiCCT1r present in the media. A reference volume (RV) of cells was
determined and cells were resuspended in 15 RV of cold buffer (10 mM Tris, pH 7.4, 10 mM NaCl, and 1 mM
MgCl2). The samples were divided in half, and 90 µg/mL PK was added to one set, while the other set was
treated with a buffer control (10 mM Tris⋅HCl, pH 7.5). After 30 min of incubation on ice, the PK was inactivated
by addition of 500 µg/mL PMSF. Cells were lysed by adding Nonidet P-40 to a final concentration of 0.3% and

homogenized in a glass Dounce homogenizer. Crude total cell lysate was then removed for future analysis (T).
Remaining lysates were centrifuged at 1,200× g for 5 min at 4 C, and the supernatant (cytoplasmic fraction) was
saved for future analysis (C). The nuclear pellet was resuspended in 10 RV of 250 mM sucrose containing 10 mM
MgCl2. A total of 10 RV of 880 mM sucrose solution containing 5 mM MgCl2 was added under the nuclear
fraction, and nuclei were purified by centrifuging at 1,200× g for 10 min at 4 C through this sucrose cushion. The
purified nuclear pellet was resuspended in 10 RV of 340 mM sucrose solution containing 5 mM MgCl2. PK
treatment was performed as before on the samples previously treated with PK. After stopping the PK reaction,
protease inhibitor (Roche) was added to each sample, and the nuclei were lysed by sonicating 3× for 30 s at 40 V
with 5 min on ice in between pulses. SDS/PAGE analysis was performed on all samples as above except samples
were run on a 15% Criterion gel (BioRad), and because the ApiCCT1r was so abundant in the media, only 10 µg of
protein was loaded from the media to avoid extreme overexposure. All other samples were 30 µg of total
protein. Samples were then analyzed by SDS/PAGE as described below.

Immunocytochemistry and Quantitation of Inclusion Bodies.
14A2.6 cells were grown as described above on UV-treated coverslips for 24 h and then induced with 2.5 µM PA
for 48 h. Cells were then fixed in 2% paraformaldehyde, permeabilized with 0.1% Triton X-100 in PBS, and nuclei
were stained with 4′,6-diamidino-2-phenylindole. Fluorescent microscopy was performed using Axiovision
software and a Zeiss AxioObserver.Z1 microscope. A minimum of 500 cells were counted from ∼5–6 fields in
three independent experiments for each data point at 20× magnification. Aggregation is expressed as the
percentage of cells with visible inclusions versus total number of cells.

SDS/PAGE of PC12 Cell Homogenates.
mHtt expression was induced with 2.5 µM PA and simultaneously treated with listed concentrations of
ApiCCT1r for 48 h with no subsequent addition of ApiCCT1r. Three independent experiments were performed. At
48 h postinduction, cells were lysed in radioimmune precipitation assay buffer [10 mM Tris, pH 7.5, 150 mM
NaCl, 1 mM EDTA (pH 8.0), 1% Nonidet P-40, 0.5% SDS] containing Complete Protease Inhibitor (Roche
Diagnostics). A DC protein assay (Bio-Rad) was performed to determine protein concentration. A total of 30 μg
lysate was added in a 1:1 ratio to loading buffer (125 mM Tris, pH 6.8, 20% glycerol, 4% SDS, 10% βmercaptoethanol, 0.004% bromophenol blue) and loaded onto a 10% Criterion gel (Bio-Rad). The gel was then
run at 125 V until the dye front reached the bottom of the gel. It was then wet-transferred to a nitrocellulose
membrane, blocked for 1 h in StartingBlock T20 (TBS) Blocking Buffer (Pierce) at room temperature and probed
with anti-EGFP (Clontech, 1:1,000), anti-Actin (Sigma Monoclonal Anti-Actin Clone AC-40 Cat No. A-4700,
1:5,000), anti-His antibody (Sigma, 1:1,000), anti-GAPDH (Imgenex, 1:1,000), or anti-p84 (AbCam, 1:1,000).
Peroxidase-conjugated AffiniPure goat anti-rabbit or anti-mouse secondary antibodies (Jackson
ImmunoResearch Laboratories) were used at 1:20,000 for 1 h at room temperature. Blots were detected using
PICO detection reagent (Pierce).

SDS-AGE of PC12 Cell Homogenates.
The analysis of mHtt by SDS-AGE with Western analysis was performed as previously described (26–29).

Filter Retardation Analysis of PC12 Cell Homogenates.
The same lysates used in the SDS/PAGE and SDS-AGE assays were also analyzed for SDS-insoluble mHtt by filterretardation assays as described in refs. 27, 28, 40.

Quantification of Western Blots.

Densitometry of the autoradiographs was performed using ImageJ software (National Institutes of Health).
Measurements were normalized to control samples treated with vehicle in all of the assays as there is no loading
control for SDS-AGE or filter-retardation assays.

Live Cell Imaging.

Time-lapse microscopy was performed as described in ref. 28. The 14A2.6 cells were grown as above, and 5 ×
105 cells were plated onto collagen-coated glass-bottom microwell dishes (MatTek, P35G-1.5–14-C). Cells were
induced with 2.5 µM PA and simultaneously treated with listed concentration of ApiCCT1r at 24 h postplating
and allowed to equilibrate in the imaging system. The amount of equilibration time was variable between
experiments, and this difference in time was accounted for in the time elapsed for analysis. Cells were then
allowed to grow for 48 h in a VivaView live cell imaging system (Olympus). Cells were imaged every 10 min for 48
h at 20× magnification every in nine different locations per well to allow for sufficient cell numbers in analysis.
Three independent experiments were performed. The “lag phase” of inclusion formation is shown as the
number of hours before the appearance of the first inclusion body.

Knock-In Cell Line.
Homozygous mutant STHdhQ109/HdhQ109 cell lines (gift from E. Cattaneo, University of Milano, Milan) were plated
in 24-well plates (0.75 × 105 cells/well) in complete medium (DMEM / 5% glucose, 10% FBS) at 33 C as described
previously (31). Experiments were plated to have five technical replicates per concentration per experiment,
with each independent experiment repeated three times. Cells were treated with listed concentrations of
ApiCCT1r concurrently with the addition of low serum medium and temperature shift with no subsequent
treatments throughout the duration of the study.

Cell Survival Assay.

Cells were treated as described above. XTT (sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium inner salt) assays were performed at 24 and 48 h after the temperature shift. At those
time points, cells were incubated for 4 h with XTT and phenazine methosulfate (0.2 mg/mL and 0.1 µg/mL,
respectively; Sigma-Aldrich), and absorbance was read at 450 nm. Higher values in the treated groups indicate
increased cellular respiration suggestive of increased cell survival.

Statistical Analysis.
All statistical analyses were performed using GraphPad Prism 5.04 software. All data are expressed as mean ± SE
of measure. P < 0.05 was considered to be statistically significant in all cases. Statistical comparisons of results
were performed by performing one-way ANOVA analysis followed by Dunnett’s multiple comparison tests.
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